These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
182 related articles for article (PubMed ID: 12041767)
1. Imipenem/cilastatin as empirical treatment of severe infections in compromised patients. Biglino A; Bonasso M; Gioannini P J Chemother; 1991 Jan; 3 Suppl 1():208-12. PubMed ID: 12041767 [TBL] [Abstract][Full Text] [Related]
2. Imipenem-cilastatin in the treatment of hospital infections. Mao P; Enrichens F; Olivero G; Sciascia C; Benedetto G; Franchello A; Olivero S J Chemother; 1991 Jan; 3 Suppl 1():205-7. PubMed ID: 12041766 [TBL] [Abstract][Full Text] [Related]
3. Imipenem/cilastatin (1.5 g daily) versus meropenem (3.0 g daily) in patients with intra-abdominal infections: results of a prospective, randomized, multicentre trial. Basoli A; Meli EZ; Mazzocchi P; Speranza V Scand J Infect Dis; 1997; 29(5):503-8. PubMed ID: 9435041 [TBL] [Abstract][Full Text] [Related]
4. Imipenem/cilastatin in the treatment of severe hospital infections. Patoia L; Menichetti F; Bucaneve G; Pasticci MB; Baratta E; Grignani F; Del Favero A Chemioterapia; 1988 Apr; 7(2):105-8. PubMed ID: 3165056 [TBL] [Abstract][Full Text] [Related]
5. How should imipenem-cilastatin be used in the treatment of fever and infection in neutropenic cancer patients? Raad II; Abi-Said D; Rolston KV; Karl CL; Bodey GP Cancer; 1998 Jun; 82(12):2449-58. PubMed ID: 9635539 [TBL] [Abstract][Full Text] [Related]
6. Intramuscular imipenem/cilastatin for treatment of mild and moderately severe bacterial infections. Keller CA; Villavicencio J; Ramirez C Scand J Infect Dis Suppl; 1987; 52():26-31. PubMed ID: 3483287 [TBL] [Abstract][Full Text] [Related]
7. Efficacy and tolerability of imipenem-cilastatin versus ceftazidime plus tobramycin as empiric therapy of presumed bacterial infection in neutropenic cancer patients. Miller JA; Butler T; Beveridge RA; Kales AN; Binder RA; Smith LJ; Ueno WM; Milkovich G; Goldwater S; Marion A Clin Ther; 1993; 15(3):486-99. PubMed ID: 8364941 [TBL] [Abstract][Full Text] [Related]
8. [Treatment of moderate or severe infections using imipenem/cilastatin. 41 cases based on a multicenter protocol]. Stahl JP; Chavanet P; Robert D; Croize J; Mercatello A; Bru JP; Aguilaniu F; Portier H; Micoud M Pathol Biol (Paris); 1986 May; 34(5):465-9. PubMed ID: 3534723 [TBL] [Abstract][Full Text] [Related]
9. Formulary review of the carbapenems: comparison of imipenem/cilastatin and meropenem. Richerson MA; Ambrose PG; Quintiliani R; Nightingale CH Conn Med; 1998 Mar; 62(3):165-9. PubMed ID: 9573653 [TBL] [Abstract][Full Text] [Related]
10. [Combination therapy of antibiotics and intravenous immunoglobulin]. Masaoka T Nihon Rinsho; 2001 Apr; 59(4):781-4. PubMed ID: 11305006 [TBL] [Abstract][Full Text] [Related]
11. Treatment of obstetric and gynecologic infections with meropenem: comparison with imipenem/cilastatin. Maggioni P; Di Stefano F; Facchini V; Irato S; Mancuso S; Colombo M; Massobrio M; Melis GB; Crosignani P J Chemother; 1998 Apr; 10(2):114-21. PubMed ID: 9603636 [TBL] [Abstract][Full Text] [Related]
12. Pharmacokinetic and clinical evaluation of serious infections in premature and newborn infants under therapy with imipenem/cilastatin. Böswald M; Döbig C; Kändler C; Krüger C; Scharf J; Soergel F; Zink S; Guggenbichler JP Infection; 1999; 27(4-5):299-304. PubMed ID: 10885853 [TBL] [Abstract][Full Text] [Related]
13. Multicenter randomized trial comparing meropenem (1.5 g daily) and imipenem/cilastatin (2 g daily) in the hospital treatment of community-acquired pneumonia. Bartoloni A; Strohmeyer M; Corti G; Buonomini MI; Franchino L; Romanelli G; Moretti AM; De Vizzi GB; Petraglia A; Mancini P; Atzeni R; Fogliani V; Giura R; Paradisi F Drugs Exp Clin Res; 1999; 25(6):243-52. PubMed ID: 10713862 [TBL] [Abstract][Full Text] [Related]
14. Imipenem/cilastatin therapy of serious infections: a U.S. multicenter noncomparative trial. Calandra GB; Hesney M; Brown KR Clin Ther; 1985; 7(2):225-38. PubMed ID: 3886144 [TBL] [Abstract][Full Text] [Related]
15. Meropenem versus imipenem/cilastatin in the treatment of sepsis in Chinese patients. Kuo BI; Fung CP; Liu CY Zhonghua Yi Xue Za Zhi (Taipei); 2000 May; 63(5):361-7. PubMed ID: 10862445 [TBL] [Abstract][Full Text] [Related]
16. [Meropenem (Merrem) vs imipenem/cilastatin in hospital treatment of intra-abdominal infections. A multicenter study]. Tonelli F Minerva Chir; 1997 Mar; 52(3):317-26. PubMed ID: 9148225 [TBL] [Abstract][Full Text] [Related]
17. A randomized, controlled clinical trial on meropenem versus imipenem/cilastatin for the treatment of bacterial infections. Hou F; Li J; Wu G; Zheng B; Chen Y; Gu J; Wang H; Huo L; Xue X; Jia C; Yin Y; Tian X; Ren S Chin Med J (Engl); 2002 Dec; 115(12):1849-54. PubMed ID: 12622937 [TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of imipenem/cilastatin (Tienam, MSD) in treating complicated infections in urology]. Derevianko II; Nefedova LA; Lavrinova LN Urologiia; 2002; (3):21-5. PubMed ID: 12180053 [TBL] [Abstract][Full Text] [Related]
19. Impact of the introduction of real-time therapeutic drug monitoring on empirical doses of carbapenems in critically ill burn patients. Fournier A; Eggimann P; Pagani JL; Revelly JP; Decosterd LA; Marchetti O; Pannatier A; Voirol P; Que YA Burns; 2015 Aug; 41(5):956-68. PubMed ID: 25678084 [TBL] [Abstract][Full Text] [Related]
20. A prospective, randomized study comparing cefepime and imipenem-cilastatin in the empirical treatment of febrile neutropenia in patients treated for haematological malignancies. Cherif H; Björkholm M; Engervall P; Johansson P; Ljungman P; Hast R; Kalin M Scand J Infect Dis; 2004; 36(8):593-600. PubMed ID: 15370671 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]